Swedbank AB Has $79.27 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Swedbank AB grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 722,243 shares of the medical equipment provider’s stock after purchasing an additional 125,843 shares during the quarter. Swedbank AB owned about 1.04% of Lantheus worth $79,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Signaturefd LLC boosted its holdings in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after acquiring an additional 100 shares in the last quarter. UMB Bank n.a. grew its holdings in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC grew its holdings in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares during the period. Finally, Moody National Bank Trust Division increased its stake in Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock valued at $1,203,000 after purchasing an additional 162 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities decreased their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Finally, Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Trading Up 3.7 %

Shares of NASDAQ:LNTH opened at $90.52 on Monday. The stock has a market cap of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51. The stock’s fifty day simple moving average is $103.13 and its two-hundred day simple moving average is $96.93. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.